{"type":"trials","record":{"id":87198,"source_id":"isrctn","external_id":"ISRCTN83325075","title":"A randomised, double-masked phase III study of the efficacy and safety of Avastin® (bevacizumab) intravitreal injections compared to best available therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration","brief_summary":"To determine the efficacy and safety of intravitreal Avastin® (bevacizumab) intravitreal injections compared to usual care (verteporfin photodynamic therapy, Macugen® or sham) in treating choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD). Please note that, as of 24/09/2008, the anticipated end date of this trial has been updated from 01/12/2007 to 05/12/2008.","overall_status":"Completed","phases":["Phase III"],"study_type":"Interventional","sponsor":"Moorfields Eye Hospital NHS Foundation Trust (UK)","enrollment":130,"countries":["United Kingdom","England"],"start_date":"2006-08-11","completion_date":"2008-12-05","last_update_date":"2012-05-10","source_url":"https://www.isrctn.com/ISRCTN83325075","editorial_summary":"A registered Phase III study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:39.792962+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Adult","comparator":null,"attribution":"Source: ISRCTN ISRCTN83325075; retrieved 2026-09-25","interventions":["Avastin® (bevacizumab), verteporfin, Macugen® (pegaptanib sodium)","Drug"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["The proportion of subjects who gain 15 letters (3 lines) or more of best corrected visual acuity score at the 12 month…","Secondary outcome measures amended as of 24/09/2008: 1. The proportion of subjects who lose fewer than 15 letters (appr…"],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD)","1. Intravitreal Avastin® (bevacizumab) with placebo PDT where necessary to maintain masking 2. Verteporfin PDT with sha…","results","Avastin® (bevacizumab), verteporfin, Macugen® (pegaptanib sodium)","Drug"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":35,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn83325075","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2006-08-11 to 2008-12-05","comparator":null,"confidence":"structured-source","population":"All · Adult","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.600Z","intervention":["Avastin® (bevacizumab), verteporfin, Macugen® (pegaptanib sodium)","Drug"],"participants":130,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Phase III","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["The proportion of subjects who gain 15 letters (3 lines) or more of best corrected visual acuity score at the 12 month…","Secondary outcome measures amended as of 24/09/2008: 1. The proportion of subjects who lose fewer than 15 letters (appr…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as Interventional."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/87198","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}